Detalhe da pesquisa
1.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet
; 398(10313): 1811-1824, 2021 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672967
2.
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
Cardiovasc Diabetol
; 21(1): 163, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002856
3.
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Circulation
; 141(10): 843-862, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31992065
4.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet
; 394(10193): 121-130, 2019 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189511
5.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med
; 376(20): 1933-1942, 2017 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28514624
6.
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(12): 2451-2459, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462955
7.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Diabetes Obes Metab
; 21(6): 1299-1304, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30714309
8.
Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
Circ J
; 81(11): 1686-1692, 2017 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28652529
9.
Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
Circ J
; 82(1): 183-191, 2017 12 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28768921
10.
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
JAMA Cardiol
; 5(10): 1136-1143, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639518
11.
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
J Am Heart Assoc
; 9(1): e014328, 2020 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31852422
12.
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
Diab Vasc Dis Res
; 16(2): 171-177, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31014095
13.
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
J Am Heart Assoc
; 8(23): e013790, 2019 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31752637
14.
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
JAMA Cardiol
; 3(5): 401-408, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29525816
15.
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Atherosclerosis
; 261: 12-18, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28412650
16.
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.
Diabetes Care
; 43(2): e22-e24, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806654
17.
Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
Circ Genom Precis Med
; 13(1): e002767, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31898914
18.
Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Am J Health Syst Pharm
; 60(12): 1251-6, 2003 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12845921
19.
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
J Hematol Oncol
; 6: 17, 2013 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23414938
20.
TRITON and beyond: new insights into the profile of prasugrel.
Cardiovasc Ther
; 30(4): e174-82, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21883999